Moteur de recherche d’entreprises européennes
Financement de l’UE (14,5 M €) : Consortium REspiratory Syncytial Virus in EUrope - Sofia réf. : 116019 Hor01/01/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Consortium REspiratory Syncytial Virus in EUrope - Sofia réf. : 116019
RSV causes severe disease and results in substantial healthcare costs in individuals at the extremes of the age spectrum and in high risk groups. RESCEU brings together academia, national public health agencies and EFPIA with proven expertise and a strong track record in RSV research. The academic partners are leaders in RSV epidemiology, clinical RSV research, health economics, and vaccinology; and key opinion leaders with advisory roles in European and national public health bodies, health technology agencies and vaccine advisory groups. EFPIA participants (AZ, GSK, JPNV, Novavax, Pfizer, and SP) have active clinical research programmes to develop lead candidates for treatment and prevention of RSV in infants, adults and the elderly. As part of RESCEU, EFPIA participants will contribute expertise in a wide range of fields including infectious disease, clinical medicine, immunology, epidemiology, biostatistics, biomarker development, global health, and health economics. RESCEU’s aim is to develop robust evidence on RSV disease burden and economic impact; create a sustainable Europe-wide multidisciplinary, multi-stakeholder community from academia, public health, scientific societies, patient organisations, regulatory agencies and industry; and provide infrastructure to perform future pivotal trials for RSV vaccines and therapeutics. RESCEU aims to provide sustainable longer term impact on RSV disease burden and thus make a significant contribution to improved health and wellbeing in Europe. The project will comprise 6 work packages. WP 1-3 will identify and marshal data from large-scale systematic reviews of epidemiological and cost studies, disease registries, linked routine (national) healthcare and claims datasets and will establish a framework for and assemble data from RSV surveillance in Europe to estimate RSV disease burden on health services and inform economic models.
| Academisch Ziekenhuis Groningen | 307 125 € |
| Astrazeneca AB | 0,00 € |
| 223 306 € | |
| Glaxosmithkline Biologicals SA | 0,00 € |
| Imperial College of Science Technology and Medicine | 860 503 € |
| Janssen Pharmaceutica N.V. | 0,00 € |
| Novavax Inc. | 0,00 € |
| Pfizer Ltd. | 0,00 € |
| 598 125 € | |
| Sanofi Pasteur SA | 0,00 € |
| Servizo Galego de Saude | 499 453 € |
| Statens Serum Institut | 508 717 € |
| Synapse Research Management Partners SL | 613 270 € |
| Teamit Research SL | 480 480 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 2 187 350 € |
| The University of Edinburgh | 3 604 783 € |
| Universitair Medisch Centrum Utrecht | 2 815 388 € |
| Universiteit Antwerpen | 1 203 875 € |
| VARSINAIS-SUOMEN SAIRAANHOITOPIIRIN KUNTAYHTYMA | 595 750 € |
https://cordis.europa.eu/project/id/116019
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Academisch Ziekenhuis Groningen - Financement de l’UE (14,5 M €) : Consortium REspiratory Syncytial Virus in EUrope - Sofia réf. : 116019"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
